Healthcare Research and Development

Health Care Research and Development (R&D)

CPTech Pages Relating to Pharmaceutical Research and Development

CPTech Documents

May, 2006. James Love. "Drug development incentives to improve access to essential medicines." Bulletin of the World Health Organization. 84 (5).

September 22, 2003. James Love. Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines Consumer Project on Technology.

December 3, 2002. James Love. The Benefits of a Treaty on R&D. PPT presentation given at The Drugs for Neglected Diseases (DND) Working Group, in Rio de Janerio, Brazil.

October 23-24, 2000. James Love. "Paying for health care R&D: Carrots and Sticks," paper presented to the MSF working group on R&D, Geneva.

James Love, "Preliminary thoughts on a program for Essential Health Research".

April 2, 2000. James Love. "How Much does it cost to develop a new drug," paper for Geneva meeting of the MSF Working Group on R&D.

CPTech Pages on R&D of Specific Drugs

Gleevec/Glivec: Cancer drug produced by Novartis developed with significant funding from the NIH. The main researcher was Dr. Brian Drucker, and there is a separate page on his involvement in the R&D of the drug.

Fuzeon/T-20: First drug in a new class of antiretrovirals known as fusion inhibitors. Discovered by researchers at Duke University, and developed with federal support.

PA-824: Pipeline tuberculosis drug in the pre-clinical stage of development. In the first agreement of its kind, Chiron licensed the patent rights to the Global Alliance for TB Drug Development, which will continue R&D on the drug. The Global Alliance will be able to use any completed drugs coming out of the R&D without paying royalties, and there's a grant-back option to Chiron for manufacture and commercialization of products in developed markets.

Stavudine (d4T):</a> Antiretroviral developed at Yale University by scientists on grants from the National Institutes of Health.

Taxol: Cancer drug developed by the government and licensed to Bristol Myers Squibb.

February, 2005. Excerpt from the Economic Report of the President. (pp168-170) Creative Ways to Encourage Innovation.

Tufts University Center for the Study of Drug Development Documents

Recent Meetings on R&D Funding

Other Documents

October 19, 2006. Government Accountability Office report requested by Rep. Waxman, Sen. Durbin and Sen. Kennedy. New Drug Development - Science, Business, Regulatory and Intellectual Property Issues Cited as Hampering Drug Development Efforts. May 2006. Virginia Barbour, Paul Chinnock, Barbara Cohen, & Gavin Yamey. "The Impact of Open Access Upon Public Health." Editorial in the Bulletin of the World Health Organization. 84 (5).

October 22, 2005. Donald W Light and Joel Lexchin in the British Medical Journal. "Foreign free riders and the high price of US."

December 15, 2004. Donald Light. Presentation at the David Rogers Health Policy In the Name of Research: Raising Prices Here and Abroad. Colloquium, Cornell University Medical College.

November, 2004. Jean Lanjouw and William Jack. Trading Up: How Much Should Poor Countries Pay to Support Pharmaceutical Innovation? Center for Global Development Brief.

September 22, 2004. Dean Baker. "Financing Drug Research: What Are the Issues?" Center for Economic and Policy Research.

April 2, 2004. "WHO leads drive for international coordination of clinical research." World Health Organization press release.

October 30, 2003. Letter from US Department of Health and Human Services to the World Health Organziation on its proposed commission on innovation, IP and public health.

October 22, 2003. GSK and Ranbaxy to Collaborate on Drug Discovery and Development.Ranbaxy press release.

March 14, 2003. John Barton. Preserving the Global Scientific and Technical Commons.

2003. University Research, Intellectual Property and Access to Essential Medicines in Resource-Poor Settings. American Medical Student Association Resolution.

2003. Table 8: R&D Abroad by Geographical Area. Excerpt from PhRMA's Annual Membership Survey for 2002.

May 28, 2002. National Institute for Health Care Management. Changing Patterns in Health Care Management. This report states that 35% of drugs approved by the FDA in the 1990s were New Molecular entities, and 65% were not. Full Report (pdf), Press release

News Stories

March 29, 2007. Washington Post editorial. A Dose of Innovation. September 30, 2005. Why New Drugs Don't Live Up to the Hype.Claudia Wallis for Time Magazine.

March 1, 2005. Let The Market Find A Cure For AIDS. Op-ed by Scott Gottleib for Forbes Magazine.

February 10, 2005. Andrew Pollack for the New York Times. "Open-Source Practices for Biotechnology."

November 29, 2004. Stephen Foley for the London Independent. "GSK Asks Blair for Tax and Patent Incentives for Research Into Neglected Diseases."

November 29, 2004. Deroy Murdock for the National Review. "Pills Don't Grow on Trees."

September 25, 2004. "Is that it, then, for blockbuster drugs?" Editorial in the Lancet.

July 15, 2004. Marcia Angell in the New York Review of Books. "The Truth About the Drug Companies."

February 24, 2004. Peter Landers for the Wall Street Journal. "Drug Industry's Big Push Into Technology Falls Short: Testing Machines Were Built To Streamline Research -- But May Be Stifling It."

January 5, 2003. "What's Next for Pharma?" Business Week interview with staff of the Tufts Center for the Study of Drug Development.

December 1, 2003. Op-ed by Merrill Goozner in the Washington Post. "Prescription For Reform."

November 15, 2003. Op-ed by Peter Lansbury, from Harvard Medical School, published in the Washington Post. "An Innovative Drug Industry? Well, No."

March 28, 2003. James Glassman for Tech Central Station. "A Different High-Tech War."

March 10, 2003. Letter to the Editor of the Scientist Magazine by Richard Klausner (Bill and Melinda Gates Foundation). "Foundations and Research Decisions."

January 13, 2003. Peg Brickley for The Scientist. "Mouse Patent Fails in Canada."

December 8, 2002. Op-ed by "Baker & McKenzie" in the Financial Times. "Why Drug Patents Matter."

October 7, 2002. Nicholas Thompson for the New Republic. "Drug Abuse; Where have all the new meds gone?"

May 29, 2002. Melody Petersen for the New York Times. "New Medicines Seldom Contain Anything New, Study Finds."

May 28, 2002. Karen Pallarito for Reuters Health. "Most New Drugs Are Me-Too Medications: Study"

May 17, 2002. Tom Burton for the Wall Street Journal. "Why Cheap Drugs that Appear to Halt Fatal Sepsis Go Unused."

April 10, 2002. Paul Mark for the Edmonton Journal. "Global drug firm likes what it sees: Edmonton biotech researchers get deal with Swiss giant."

February 25, 2002. PhRMA, Health Care Advocates To Fight Efforts By Generic Industry To Jeopardize the Progress In Medical Research. Also, see the full statement of Richard Smith, PhRMA's Vice President of Policy and Research. PhRMA Press Release.

January 29, 2002. Chris Adams and Scott Hensley for the Wall Street Journal. "Drug Makers Plan to Push the FDA To Move Quicker With Approvals."

January 23, 2002. Peter Gorner for the Chicago Tribune. "Many scientists won't share research data, study finds."

October, 2001. The Economics of TB Drug Development. The Global Alliance of TB Drug Development.

July 9, 2001. WHO and Top Publishers Announce Breakthrough on Developing Countries' Access to Leading Biomedical Journals. World Health Organization press release.

July 9, 2001. Melody Petersen for the New York Times. "Medical Journals to Offer Lower Rates in Poor Nations."

April 26, 2001. Philip Webster for The Times. (UK) "Charity Tax deal for Drugs Firms."

February 11, 2001. Sheryl Gay Stolberg in the New York Times. "Children Test New Medicines Despite Doubts."

December, 2000. Washington Post Series. The Body Hunters "Six part series on ethical problems related to the poorly regulated international system of pharmaceuticals testing."

December, 2000. Intellectual Property Rights and Global Health: Challenges for Access and R&D. The Wellcome Trust, the Institute for Global Health, and the Commission on Macroeconomics and Health.

May 15, 1996. Prescription Treatment for Obesity Result of Government-University-Industry Partnership. MIT press release.

About Search Events Listserves Blogs Recent